In summary, our findings demonstrated a significant correlation among PLOD gene expression, tumor prognosis, and cancer immune microenvironment, indicating that PLOD family members may mediate tumor progression and exert immunotherapeutic effects on HCC. The gene discussed is PLOD1; the disease is hepatocellular carcinoma.